Motif Bio PLC - AIM cash shell - Says requested and granted extension to filing deadline for 2019 results to September 30 from June 30. Audit process has begun but delayed by change of auditor to Crowe UK LLP from Pricewaterhouse Coopers LLP. Notes that if doesn't make an acquisition that is classified as a reverse takeover, its shares will be suspended from trading on AIM and cancelled six months after that. Motif Bio became a cash shell earlier this year after selling all assets related to antibiotic drug iclaprim.
Current stock price: 0.64 pence
Year-to-date change: up 64%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.